24/02/2023 - Institutional news
It is led by Dr. Mario Cáceres, ICREA researcher who joins IMIM-Hospital del Mar in its talent attraction program. The group focuses on the application of the latest techniques in the field of genomics to analyze the relationship between changes in the genome and various fields of health. Dr. Mario Cáceres joins IMIM-Hospital del Mar heading a new research group, the Comparative and Functional Genomics Research Group. The arrival of Dr. Cáceres Aguilar, ICREA researcher, has come about thanks to the talent attraction program launched at the institution to boost the research carried out with top-level researchers.
22/12/2022 - Institutional news
The European Medicines Agency selected Hospital del Mar Medical Research Institute and the Hospital del Mar to be a Data Partner of the DARWIN EU® data network, an EU-wide federated network of high-quality observational healthcare databases across Europe, that provides expertise and services to support regulatory decision-making throughout the lifecycle of medicinal products. The Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) is one of the first eight European centres currently selected to participate in the European Union's DARWIN EU® initiative to carry out multicentre observational studies on medicines. The data available to these partners will be used for studies to generate real-world evidence that will support scientific evaluations and regulatory decision making.
18/08/2020 - Institutional news
Dra. Jana Selent, coordinator of the GPCR drug discovery group, has been selected as the featured author of the month for the August edition in the journal Nature Methods. Recently, the Group of Dra. Selent published his latest article GPCRmd uncovers the dynamics of the 3D-GPCRome in this journal, where she presents a new tool to study one of the key elements in cell signaling, G protein-coupled receptors (GPCRs) which are the target of almost 40% of current drugs. This tool, the GPCRmd platform, will help improve our understanding of the function of these receptors, which are critical for transmitting signals to the interior of cells. The design of this tool has been made possible thanks to a consortium of researchers from 23 different institutions of 10 different European countries and the United States, led by the group of Dr. Jana Selent and with important contributions from researchers of the Paul Scherrer Institute (PSI) in Switzerland and the Autonomous University of Barcelona.
Més informació "Nature Methods selects Jana Selent as the featured author of the month for August"
10/07/2018 - Institutional news
On June 8th, Dr Jordi Mestres, coordinator of the IMIM Systems Pharmacology Research Group, was elected Fellow of the Royal Society of Chemistry of the United Kingdom. Achieving this status is an important milestone in a researcher's career as it indicates scientific quality and is one of the most important recognitions a chemist can receive. The Royal Society of Chemistry is a non-profit organisation that is more than 175 years old and has more than 54,000 members across the world. Its aim is to advance excellence in the chemical sciences, investing in the education of future generations, creating and maintaining standards, encouraging innovation, and advising governments.
Més informació "Jordi Mestres elected Fellow of the Royal Society of Chemistry"
19/04/2018 - Institutional news
The 3rd European Conference on Translational Bioinformatics (ECTB2018) was held on April 16th-17th at the premises of the Barcelona Biomedical Research Park (PRBB) with the attendance of more than 130 European scientists, developers, and entrepreneurs, interested in translating genomics and bioinformatics research into healthcare tools and services. The conference aimed to give the participants a unique experience and a forum for discussing fresh scientific results in the translational domain. The conference brought together world-leading scientists in the area which highlighted on their presentations the recent advances in information technologies that are facilitating translational research and precision medicine. Some of the topics addressed were Big Data integration and analysis, Personalized Medicine, Genome Sequencing initiatives, etc, delivered by scientists from Europe, Canada and the USA.
The Hospital del Mar Medical Research Institute (IMIM) and the Pompeu Fabra University (UPF) have just published a comment in the prestigious journal Nature Reviews Drug Discovery where they explain the excellent results from eTOX, a project that has facilitated a new model for collaboration among pharmaceutical companies, as well as between these and academia, where data and knowledge are shared for the purposes of improving the toxicological evaluation of drugs. Apart from the results obtained, which are extremely valuable, the project is a model of Open Innovation, where various public and private stakeholders join forces and actively collaborate. In addition, it has confirmed the enormous value of the data obtained in the regulatory studies conducted by the pharmaceutical industry, and has verified the fact that exploiting these requires a significant effort in terms of extraction, standardisation, and integration.
Més informació "Open innovation improving drug safety evaluation"
01/06/2017 - Institutional news
The Josep Carreras Leukemia Research Institute announced today that it has entered into a collaboration agreement with Chemotargets, an IMIM's spin-off. The aim of the collaboration is to further understand the mechanism of action of some active hits in leukemia discovered at IJC, and exploit this information to identify new chemical entities with improved pharmacology and safety profiles using Chemotargets’ precision modeling platform. The acute myeloid leukemia (AML) research group, directed by Dr. Ruth M. Risueño, recently published a study in which the importance of serotonin receptor subtype 1 (HTR1) in AML was highlighted (Etxabe et al. Leukemia 2017). “We observed that AML cells differentially expressed HTR1 compared with healthy blood cells and the most primitive hematopoietic fraction; in fact, HTR1B expression in AML patient samples correlated with the clinical outcome”, said Dr. Risueño. “Based on these results and other projects developed in the group, we discovered some active hits on HTR1 and other receptors with antileukemia effects; these represent excellent starting points for a drug discovery program and Chemotargets’ platform will be of great help in this process”.
02/03/2017 - Institutional news
From 20th to 22nd March, Barcelona will host the most important European partnering conference in the biotech and pharma sectors. The aim of this International Conference is to bring together pharmaceutical, biotechnology and financial firms to form alliances and partnerships for achieving common goals. More than 1,400 companies from 45 countries are expected to participate, with more than 2,400 people attending. In this edition, Chemotargets, the IMIM spin-off dedicated to developing software for predicting the mechanism of action and safety of new drugs, directed by Dr. Jordi Mestres, Coordinator of the Systems Pharmacology research group at the GRIB (IMIM-UPF), is one of the 5 biotech companies from Barcelona invited to take part.
Més informació "Chemotargets, one of the five top Biotechs at BIO Europe Spring 2017"
The Carlos III Health Institute (ISCIII in Spanish) will fund, in the framework of the “International Rare Disease Research Consortium (IRDiRC)", three collaboration research projects in the whole of Spain, one of which is “DRUGS4RARE: drug repositioning for rare diseases”. This project is lead by Barcelona Science Park (PCB in Spanish), with the participation of the IMIM, together with the University of Santiago de Compostela (USC).
27/01/2011 - Institutional news
Jordi Mestres at the Editorial Board of the new publication "Scientific Reports" Jordi Mestres, head of Chemogenomics laboratory of GRIB (IMIM-UPF) has been appointed member of the Editorial Board of Scientific Reports, the new primary research publication from the publishers of Nature, covering all areas of the natural sciences –biology, chemistry, physics, and earth sciences.
Més informació "Jordi Mestres at the Editorial Board of the new publication "Scientific Reports"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
